Los Angeles Capital Management
DNLI icon

Los Angeles Capital Management’s Denali Therapeutics DNLI Stock Holding History

Los Angeles Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.1K Sell
627
-300
-32% -$6.16K ﹤0.01% 1848
2026
Q1 		$17.8K Buy
927
+300
+48% +$5.97K ﹤0.01% 1777
2025
Q4 		$10.3K Buy
+627
New +$10.6K ﹤0.01% 2070
2025
Q1 		– Sell
-22,222
Closed -$453K – 1119
2024
Q4 		$453K Sell
22,222
-5,718
-20% -$146K ﹤0.01% 834
2024
Q3 		$814K Sell
27,940
-24,923
-47% -$618K ﹤0.01% 715
2024
Q2 		$1.23M Sell
52,863
-2,749
-5% -$52.8K ﹤0.01% 584
2024
Q1 		$1.14M Buy
55,612
+9,054
+19% +$170K ﹤0.01% 655
2023
Q4 		$999K Buy
46,558
+556
+1% +$11K ﹤0.01% 670
2023
Q3 		$949K Buy
46,002
+1,046
+2% +$26.5K ﹤0.01% 659
2023
Q2 		$1.33M Buy
44,956
+26,449
+143% +$744K 0.01% 586
2023
Q1 		$426K Sell
18,507
-2,395
-11% -$65.9K ﹤0.01% 901
2022
Q4 		$581K Sell
20,902
-21,839
-51% -$650K ﹤0.01% 854
2022
Q3 		$1.31M Sell
42,741
-1,178
-3% -$38.3K 0.01% 609
2022
Q2 		$1.29M Buy
43,919
+1,667
+4% +$43.7K 0.01% 642
2022
Q1 		$1.36M Buy
42,252
+1,160
+3% +$39.9K 0.01% 654
2021
Q4 		$1.83M Sell
41,092
-430
-1% -$20.4K 0.01% 538
2021
Q3 		$2.1M Buy
41,522
+8,090
+24% +$456K 0.01% 524
2021
Q2 		$2.62M Buy
33,432
+16,457
+97% +$1.02M 0.01% 523
2021
Q1 		$969K Sell
16,975
-4,101
-19% -$275K ﹤0.01% 911
2020
Q4 		$1.76M Buy
21,076
+12,025
+133% +$727K 0.01% 705
2020
Q3 		$324K Sell
9,051
-6,829
-43% -$206K ﹤0.01% 1246
2020
Q2 		$384K Sell
15,880
-4,170
-21% -$98K ﹤0.01% 1211
2020
Q1 		$351K Buy
+20,050
New +$418K ﹤0.01% 1012

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Los Angeles Capital Management's DNLI Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Denali Therapeutics (DNLI) stake by 32% in Q2 2026, selling an estimated $6.16K and leaving 627 shares worth $16.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1848.

Los Angeles Capital Management first reported a position in DNLI in Q1 2020 and has held it in 23 quarters since. The position peaked at $2.62M in Q2 2021. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Los Angeles Capital Management held 627 shares of Denali Therapeutics worth $16.1K as of Q2 2026.
  • Los Angeles Capital Management sold 300 Denali Therapeutics shares in Q2 2026, an estimated $6.16K.
  • Denali Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1848 holding.
  • Los Angeles Capital Management first reported a position in Denali Therapeutics in Q1 2020 and has held it in 23 quarters since.
  • Los Angeles Capital Management's Denali Therapeutics position peaked at $2.62M in Q2 2021.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.